Actively Recruiting
cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas
Led by Centre Jean Perrin · Updated on 2025-12-01
59
Participants Needed
3
Research Sites
298 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this ancillary clinical trial is to evaluated circulating DNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carninoma. The main question it aims to answer is : \- Does circulating DNA (cDNA) be able to detect residual disease 3 months after the end of chemoradiotherapy ? Researchers will compare detection of cDNA at 3-months and objective response (clinical and radiological). Participants will : * be included in the main study (Neck-TAR) * have a blood sample 1 and 3-month after the end of treatment
CONDITIONS
Official Title
cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient included in NeckTAR study
- Written informed consent signed for NeckTAR-IN study
- Affiliation to the French social security system
You will not qualify if you...
null
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Centre Jean PERRIN
Clermont-Ferrand, Puy-de-Dôme, France, 63011
Actively Recruiting
2
Hôpital de la Croix-Rousse
Lyon, France
Actively Recruiting
3
CHU de Saint-Étienne
Saint-Etienne, France
Actively Recruiting
Research Team
A
Angeline GINZAC COUVÉ Project manager, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SCREENING
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here